Pharmacokinetics of tobramycin in adults with cystic fibrosis: Implications for once-daily administration
Pharmacokinetics of tobramycin in adults with cystic fibrosis: Implications for once-daily administration
复制标题
DOI：
10.1128/aac.44.4.809-813.2000
复制
发表时间：
2000-04-01
影响因子：
4.9
通讯作者：
Shapiro, BJ
中科院分区：
文献类型：
--
作者：
Beringer, PM;Vinks, AATMM;Shapiro, BJ
许多机构常规使用每日一次的氨基糖苷类药物。然而，缺乏囊性纤维化（CF）患者的比较疗效数据。本研究的目的是比较每24小时（q24小时）、q12小时和q8小时给药10 mg/kg体重/天妥布霉素的预测药效学活性，药代动力学（PK）数据来自对60例成年CF患者血清药物浓度的分析。采用个体最大后验概率贝叶斯PK参数值构建血清浓度-时间曲线，测定各指标（浓度峰/MIC比[peak/MIC]、浓度-时间曲线下面积/MIC比[AUC/MIC]、浓度低于MIC的时间[T]）
Once-daily administration of aminoglycosides is routinely used in many institutions. However, comparative efficacy data for patients with cystic fibrosis (CF) are lacking. The purpose of the present study was to compare the predicted pharmacodynamic activity of tobramycin at 10 mg/kg of body weight/day administered every 24 h (q24h), q12h, and q8h, Pharmacokinetic (PK) data were derived from analysis of data on the drug concentration in sera from 60 adult CF patients. Individual maximum a posteriori probability Bayesian PK parameter values were used to construct serum concentration-versus-time curves and to determine various indices (peak concentration/MIC ratio [peak/MIC], area under the concentration-time curve/MIC ratio [AUC/MIC], and time that the concentration was less than the MIC [T